Collaboration to deliver new vaccine adjuvants
In 2021 we established a strategic collaboration with the Danish government’s life science research institute, Statens Serum Institute (SSI).
This will enable accelerated trials of alternatives to traditional aluminium-based adjuvants. Our range of patented and novel adjuvants brings new opportunities to impact diseases where current adjuvant technologies have not resulted in effective vaccines. For example, one novel adjuvant enables prophylactic, or preventative, vaccines to induce strong antibody responses against tuberculosis, chlamydia, group-A streptococcus, malaria, influenza, COVID-19 and RSV.